| Target Price | CN¥369.84 |
| Price | CN¥264.41 |
| Potential |
39.87%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Beone Medicines-h 2027 .
The average Beone Medicines-h target price is CN¥369.84.
This is
39.87%
register free of charge
CN¥476.81
80.33%
register free of charge
CN¥308.66
16.73%
register free of charge
|
|
| A rating was issued by 12 analysts: 11 Analysts recommend Beone Medicines-h to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Beone Medicines-h stock has an average upside potential 2027 of
39.87%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion CN¥ | 38.23 | 47.04 |
| 40.46% | 23.06% | |
| EBITDA Margin | 9.23% | 18.34% |
| 168.74% | 98.60% | |
| Net Margin | 3.82% | 12.89% |
| 120.89% | 237.32% |
7 Analysts have issued a sales forecast Beone Medicines-h 2026 . The average Beone Medicines-h sales estimate is
This results in the following potential growth metrics:
7 Beone Medicines-h Analysts have issued a net profit forecast 2026. The average Beone Medicines-h net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share CN¥ | 0.98 | 4.13 |
| 126.92% | 321.43% | |
| P/E | 64.10 | |
| EV/Sales | 5.44 |
7 Analysts have issued a Beone Medicines-h forecast for earnings per share. The average Beone Medicines-h EPS is
This results in the following potential growth metrics and future valuations:
Beone Medicines-h...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


